#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15190	16S	1529	1529	99.93	16S.l15.c30.ctg.1	2371	782.3	0	.	n	.	0	C1450T	SNP	1450	1450	C	1855	1855	T	943	T,G,C	941,1,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15190	16S	1529	1529	99.93	16S.l15.c30.ctg.1	2371	782.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1589	1589	C	937	C,T	935,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15190	16S	1529	1529	99.93	16S.l15.c30.ctg.1	2371	782.3	0	HET	.	.	.	A69G	.	69	69	A	474	474	A	945	A,G	742,201	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25590	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4393	726.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	2108	2108	A	1076	A,T,G,C	1073,1,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25590	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4393	726.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2742	2742	C	962	C,T,A,G	957,3,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25590	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4393	726.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2816	2816	A	868	A	866	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25590	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4393	726.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	3368	3368	C	926	C,G,A	924,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Z_01426c	folP.WHO_Z_01426c	1	1	539	2366	folP	852	852	99.88	folP.l6.c17.ctg.1	2064	143.0	0	.	p	.	0	E151K	NONSYN	451	453	GAA	1052	1054	AAA	218;216;215	A,T;A;A	217,1;216;215	.	.
folP.WHO_Z_01426c	folP.WHO_Z_01426c	1	1	539	2366	folP	852	852	99.88	folP.l6.c17.ctg.1	2064	143.0	1	SNP	p	R228S	1	.	.	682	684	AGC	1283	1285	AGC	250;252;256	A;G;C,T	250;252;255,1	folP.WHO_Z_01426c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5526	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3887	176.9	1	SNP	p	S91F	0	.	.	271	273	TCC	859	861	TCC	188;187;187	T;C,G;C	188;186,1;187	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5526	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3887	176.9	1	SNP	p	D95G	0	.	.	283	285	GAC	871	873	GAC	198;198;198	G;A,T;C	198;197,1;198	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5526	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3887	176.9	1	SNP	p	D95N	0	.	.	283	285	GAC	871	873	GAC	198;198;198	G;A,T;C	198;197,1;198	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	2098	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1860	140.7	1	SNP	p	G45D	0	.	.	133	135	GGC	726	728	GGC	235;235;234	G;G;C	235;234;234	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1054	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1589	82.8	0	.	n	.	0	A197.	DEL	197	197	A	853	853	A	210	A,C	209,1	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5230	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3512	185.4	1	SNP	p	D86N	0	.	.	256	258	GAC	882	884	GAC	234;232;234	G,A;A,C;C,G	233,1;231,1;233,1	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5230	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3512	185.4	1	SNP	p	S87I	0	.	.	259	261	AGT	885	887	AGT	234;234;234	A;G;T	234;234;234	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5230	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3512	185.4	1	SNP	p	S87R	0	.	.	259	261	AGT	885	887	AGT	234;234;234	A;G;T	234;234;234	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5230	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3512	185.4	1	SNP	p	S87W	0	.	.	259	261	AGT	885	887	AGT	234;234;234	A;G;T	234;234;234	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5230	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3512	185.4	1	SNP	p	S88P	0	.	.	262	264	TCC	888	890	TCC	231;231;232	T;C,T;C,A,G	231;230,1;230,1,1	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4510	parE	1986	1986	100.0	parE.l6.c17.ctg.1	3146	178.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1784	1786	GGC	263;260;262	G;G,A;C	263;259,1;262	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	4096	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2823	180.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1547	1549	GCA	237;234;234	G,C;C,G;A,G	236,1;233,1;233,1	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4096	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2823	180.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1550	1552	ATC	233;235;232	A,C;T,G;C,G	232,1;234,1;231,1	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4096	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2823	180.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1562	1564	GTG	238;240;243	G,T;T,G;G	237,1;239,1;243	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4096	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2823	180.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1562	1564	GTG	238;240;243	G,T;T,G;G	237,1;239,1;243	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4096	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2823	180.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2066	2068	ACC	216;216;215	A;C;C	216;216;215	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4096	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2823	180.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2120	2122	GCG	221;223;227	G;C;G,T	221;223;226,1	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4096	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2823	180.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2120	2122	GCG	221;223;227	G;C;G,T	221;223;226,1	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4096	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2823	180.5	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2243	2245	GGC	250;249;248	G,C;G;C	249,1;249;248	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4096	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2823	180.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2252	2254	GGC	247;249;248	G,A;G;C	246,1;249;248	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4096	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2823	180.5	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2270	2272	CTG	257;254;255	C,A;T,C;G	256,1;253,1;255	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5812	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3575	202.2	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1904	1906	CCG	236;238;244	C;C,T;G	236;237,1;244	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2860	porA	1146	1146	99.65	porA.l6.c17.ctg.1	2199	162.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	721	721	C	212	C,T	211,1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	288	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	384	29.2	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	26;28;28	T;T;A	26;28;28	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	288	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	384	29.2	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	65;65;65	C;A;T	65;65;65	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	288	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	384	29.2	0	.	p	.	0	D274S	NONSYN	820	822	GAT	62	64	AGT	65;65;65	A;G;T	65;65;65	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	288	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	384	29.2	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	65;65;65	T;A,C;C,A	65;64,1;64,1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	288	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	384	29.2	0	.	p	.	0	R307A	NONSYN	919	921	AGA	161	163	GCA	2;2;2	G;C;A	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	288	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	384	29.2	0	.	p	.	0	T311A	NONSYN	931	933	ACA	173	175	GCA	2;2;2	G;C;A	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	288	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	384	29.2	0	.	p	.	0	E312D	NONSYN	934	936	GAA	176	178	GAC	2;2;2	G;A;C	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	288	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	384	29.2	0	.	p	.	0	F314I	NONSYN	940	942	TTC	182	184	ATC	2;2;2	A;T;C	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	288	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	384	29.2	0	.	p	.	0	A316S	NONSYN	946	948	GCG	188	190	TCG	2;2;2	T;C;G	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	288	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	384	29.2	0	.	p	.	0	V318A	NONSYN	952	954	GTC	194	196	GCC	2;2;2	G;C;C	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	288	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	384	29.2	0	.	p	.	0	G319S	NONSYN	955	957	GGC	197	199	AGC	2;2;2	A;G;C	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	288	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	384	29.2	0	.	p	.	0	G320A	NONSYN	958	960	GGT	200	202	GCC	2;2;2	G;C;C	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	288	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	384	29.2	0	.	p	.	0	G322V	NONSYN	964	966	GGT	206	208	GTT	2;3;3	G;T;T	2;3;3	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	288	porB1a	984	100	94.0	porB1a.l15.c17.ctg.3	544	22.1	0	.	p	.	0	M18T	NONSYN	52	54	ATG	496	498	ACG	50;49;45	A;C;G	50;49;45	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	288	porB1a	984	100	94.0	porB1a.l15.c17.ctg.3	544	22.1	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	538	540	CAA	11;11;9	C;A;A	11;11;9	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2694	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	2036	164.6	0	.	p	.	0	N38E	NONSYN	112	114	AAT	696	698	GAA	239;241;240	G;A,C;A	239;240,1;240	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2694	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	2036	164.6	0	.	p	.	0	N134D	NONSYN	400	402	AAT	984	986	GAT	237;238;236	G,C;A,C;T	236,1;237,1;236	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2694	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	2036	164.6	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1107	1109	TCA	225;224;224	T;C,A;A,G	225;223,1;223,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2694	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	2036	164.6	0	.	p	.	0	S217G	NONSYN	649	651	AGT	1233	1235	GGT	227;224;224	G,A;G;T	226,1;224;224	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2694	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	2036	164.6	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1236	1238	GTC	222;222;224	G,A,C;T,A,C;C	220,1,1;220,1,1;224	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2694	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	2036	164.6	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1248	1250	TCT	235;235;235	T;C,T;T	235;232,3;235	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2694	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	2036	164.6	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1566	1568	GCA	200;201;201	G;C;A,T	200;201;200,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2694	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	2036	164.6	1	SNP	p	G120K	1	.	.	358	360	AAG	942	944	AAG	237;237;234	A;A,C;G,T	237;236,1;233,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2694	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	2036	164.6	1	SNP	p	A121D	1	.	.	361	363	GAC	945	947	GAC	232;234;235	G;A;C,G	232;234;234,1	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2694	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	2036	164.6	1	SNP	p	D121N	0	.	.	361	363	GAC	945	947	GAC	232;234;235	G;A;C,G	232;234;234,1	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	9498	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5383	219.9	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2245	2247	AAT	268;266;268	A;A,G,C;T,A	268;264,1,1;266,2	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1386	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1431	120.6	1	SNP	p	V57M	1	.	.	169	171	ATG	722	724	ATG	245;247;248	A;T;G	245;247;248	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
